Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ:CYCC opened at $2.65 on Thursday. The company’s 50-day moving average is $2.21 and its 200 day moving average is $3.69. The company has a market capitalization of $3.50 million, a P/E ratio of -0.10 and a beta of 0.54. Cyclacel Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $13.20.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.35) by $0.12. The company had revenue of $0.03 million during the quarter. As a group, research analysts predict that Cyclacel Pharmaceuticals will post -18.7 earnings per share for the current year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.